학술논문
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer
Document Type
Article
Author
Bischoff, P.; Reck, M.; Overbeck, T.; Aydilek, E.; Christopoulos, P.; Thomas, M.; Rittmeyer, A.; Lüders, H.; Grohé, C.; Kollmeier, J.; Kulhavy, J.; Hummel, H.-D.; Kemper, M.; Bleckmann, A.; Reinmuth, N.; Röper, J.; Griesinger, F.; Janning, M.; Sommer, L.; Tritchkova, G.; Wermke, M.; Aguinarte, L.; Sebastian, M.; Stratmann, J.; Koch, M.; Wiesweg, M.; Loges, S.; Wesseler, C.; Waller, C.F.; Kauffmann-Guerrero, D.; Stenzinger, A.; Stephan-Falkenau, S.; Trautmann, M.; Lassmann, S.; Tiemann, M.; Klauschen, F.; Wolf, J.; Süptitz, J.; Frost, N.; Hilbrandt, M.; Schmidt, B.; Raspe, M.; Schütte, W.; Grah, C.; Velthaus, J.-L.; Kopp, H.-G.; Horter, S.; Keymel, S.; Papić, D.; Florian, S.; Horst, D.; Wild, P.J.
Source
In: Journal of Thoracic Oncology . (Journal of Thoracic Oncology, May 2024, 19(5):803-817)
Subject
Language
English
ISSN
15561380
15560864
15560864